Director, Pharmacovigilance & Safety Technology
Alnylam Pharmaceuticals
Director, Pharmacovigilance & Safety Technology
Alnylam Pharmaceuticals
Develops RNAi-based therapies for genetic diseases
Overview
Alnylam is the world’s leading RNA interference (RNAi) company, dedicated to transforming patients’ lives through innovative medicines. As the global development and commercial portfolio expands, Safety & Risk Management requires scalable, compliant, and data-driven technology capabilities that support high-quality pharmacovigilance across investigational and marketed products.
The Director, Pharmacovigilance & Safety Technology shapes and executes the technology strategy for Safety & Risk Management and related safety functions. As the primary business technology leader for Safety, this role ensures that platforms, data, integrations, analytics, reporting, and digital workflows enable compliant, efficient, inspection-ready, and insight-driven operations across the product lifecycle.
Reporting to the Executive Director, Commercial & Development Technologies, this role directly manages two experienced technology professionals at the Manager and Senior Manager levels. The role translates Safety priorities into a practical roadmap and leads execution and additional work through its team, product owners, application teams, managed service providers, vendors, and cross-functional partners.
Success in this role requires strong pharmacovigilance-domain business acumen, technical fluency across regulated safety platforms, and the ability to translate safety priorities into a practical technology roadmap. The leader will be expected to connect strategy to execution—partnering with Safety leadership, enterprise Technology, Data, Quality, Security, Compliance, Validation, and vendor teams to deliver scalable, compliant, secure, and user-centered solutions. Rather than serving as a single-system product owner or duplicating Safety Operations responsibilities, this role provides functional technology leadership across the broader PV and safety capability landscape.
This role is Hybrid, based in Cambridge, MA requiring 2-3 days onsite.
Key Responsibilities
Qualifications:
About Alnylam
We are the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded based on Nobel Prize-winning science, our work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of RNAi therapeutics possible. Guided by core values like fierce innovation, purposeful urgency, and passion for excellence, our open and inclusive culture drives everything we do. We are proud to be globally recognized as a top employer, where people feel valued and breakthrough thinking flourishes.
About Alnylam
We are the leader in RNAi therapeutics – a revolutionary approach with the potential to transform the lives of people with rare and common diseases. Built on Nobel Prize-winning science, Alnylam has delivered the breakthroughs that made RNAi therapeutics possible and are just at the beginning of what’s possible. Our deep pipeline, late-stage programs, and bold vision reflect our core values: fierce innovation, passion for excellence, purposeful urgency, open culture and commitment to people. We're proud to be a globally recognized top employer, where an authentic, inclusive culture and breakthrough thinking fuel one another.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. Qualified applicants will receive consideration for employment without regard to their sex, gender or gender identity, sexual orientation, race, color, ethnicity, national origin, ancestry, citizenship, religion, creed, physical or mental disability, pregnancy status or related conditions, genetic information, veteran or military status, marital or familial status, political affiliation, age, or any other factor protected by federal, state, or local law. Alnylam is an E-Verify Employer.
Before applying, please review Alnylam's Candidate Privacy Notice regarding how Alnylam handles Personal Data you provide with your application for employment.
#LI-LN1
The pay range below reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on a number of factors including, but not limited to, relevant experience, skills, and education. This role is eligible for an annual short-term incentive award (e.g., bonus or sales incentive) and an annual long-term incentive award (e.g., equity).
Alnylam’s robust Total Rewards package is designed to support your overall health and well-being. We offer comprehensive benefits including medical, dental, and vision coverage, life and disability insurance, a lifestyle reimbursement program, flexible spending and health savings accounts and a 401(k)with a generous company match. Eligible employees enjoy paid time off, wellness days, holidays, and two company-wide recharge breaks. We also offer generous family resources and leave. Our commitment to your well-being reflects our belief that caring for our people fuels the impact we create together.
Learn more about these and additional benefits offered by Alnylam by visiting the Benefits section of the Careers website: https://www.alnylam.com/careers
U.S. Pay Range 187400 - 253600 USD
Develops RNAi-based therapies for genetic diseases
Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.
Explore more opportunities at Alnylam Pharmaceuticals